US · Healthcare · Biotechnology
EPS came in at -2.84 against a street estimate of -1.10 — a miss of 158.2%.
Analysts rate Faeth Therapeutics, Inc. a strong buy (14 buy, 0 hold, 0 sell out of 14) with an average price target of $56.67.
| Fund | Stake |
|---|---|
| Suvretta Capital Management, LLC | 7.82% |
| venBio Select Advisor LLC | 5.59% |
| Baker Bros Advisors LP | 4.98% |
| Balyasny Asset Management LLC | 4.03% |
| Cormorant Asset Management, LLC | 3.98% |
| Vivo Capital, LLC | 2.79% |
| RA Capital Management, LLC | 2.79% |
| Fairmount Funds Management LLC | 2.79% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 FAETH THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Board size increased from 5 to 6 directors on September 11, 2026 • New director receives e | 2026-09-17 |
| Quarterly report · Q2 2026 FAETH THERAPEUTICS, INC. — 10-Q SUMMARY For Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Cash and marketable securities: $186.4 million as of | 2026-08-04 |
| Results announced · Q3 2026 FAETH THERAPEUTICS Q2 2026 FINANCIAL RESULTS & UPDATES HEADLINE NUMBERS • Cash position: $186.4 million in cash, cash equivalents and marketable sec | 2026-08-04 |
| Board / officer change · Q3 2026 FAETH THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Stock Price Hurdle Target: $70.00 per share (average closing price over 30 consecutive tra | 2026-07-23 |
| Material agreement · Q2 2026 FAETH THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company entered into At-The-Market (ATM) offering agreement on June 18, 2026 with TD Secur | 2026-06-18 |
| Board / officer change · Q2 2026 FAETH THERAPEUTICS, INC. — 8-K SUMMARY (June 10-15, 2026) BUSINESS & SEGMENT HIGHLIGHTS • Company formerly known as Sensei Biotherapeutics, Inc. off | 2026-06-15 |
| Quarterly report · Q1 2026 SENSEI BIOTHERAPEUTICS, INC. — Q1 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Net Loss Q1 2026: $170.2 million (vs. $6.9 million in Q1 2025) — spike d | 2026-05-15 |
| Proxy statement · Q2 2026 SENSEI BIOTHERAPEUTICS PROXY SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal No. 1: Elect directors Bob Holmen and Kristian Humer to Board until | 2026-04-27 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Faeth Therapeutics, Inc. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.